Dimethyl fumarate - Almirall

Drug Profile

Dimethyl fumarate - Almirall

Alternative Names: LAS-41008; Skilarence

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almirall S.A.
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Marketed Plaque psoriasis

Most Recent Events

  • 01 Aug 2018 Almirall plans to market dimethyl fumarate in European Union, Iceland, Norway and Switzerland
  • 06 Nov 2017 Launched for Plaque psoriasis in Austria, Denmark, Sweden, Germany and Norway (PO)
  • 27 Jul 2017 Launched for Plaque psoriasis in United Kingdom (PO) before July 2017 - First Global Launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top